Dunn, J. S.; Sheehan, H. L.; McLetchie, N. G. B. (1943). "Necrosis of Islets of Langerhans Produced Experimentally". Lancet. 241 (6242): 484–487. doi:10.1016/S0140-6736(00)42072-6.
Lenzen, Sigurd[in German]; Munday, Rex (September 1991). "Thiol-group reactivity, hydrophilicity and stability of alloxan, its reduction products and its N-methyl derivatives and a comparison with ninhydrin". Biochemical Pharmacology. 42 (7): 1385–1391. doi:10.1016/0006-2952(91)90449-F.
Endo, Takeshi; Kudo, Akira; Okawara, Makoto (1 November 1979). "Reduction of Alloxan by Cyanide Ion. Isolation of Alloxan Radical Anion Salts and Alloxantin". Bulletin of the Chemical Society of Japan. 52 (11): 3473–3474. doi:10.1246/bcsj.52.3473.
Mrozikiewicz, A.; Kielstrokczewska-Mrozikiewicz, D.; Lstrokowicki, Z.; Chmara, E.; Korzeniowska, K.; Mrozikiewicz, P. M. (1994). "Blood Levels of Alloxan in Children with Insulin-dependent Diabetes Mellitus". Acta Diabetologica. 31 (4): 236–237. doi:10.1007/bf00571958. PMID7888696. S2CID12726659.
Czerwiñska, Małgorzata; Sikora, Adam; Szajerski, Piotr; Adamus, Jan; Marcinek, Andrzej; Gȩbicki, Jerzy; Bednarek, Paweł (1 June 2006). "Mechanistic Aspects of Alloxan Diabetogenic Activity: A Key Role of Keto−Enol Inversion of Dialuric Acid on Ionization". The Journal of Physical Chemistry A. 110 (22): 7272–7278. doi:10.1021/jp0614594.
Danilova I.G.; Sarapultsev P.A.; Medvedeva S.U.; Gette I.F.; Bulavintceva T.S.; Sarapultsev A.P. (2014). "Morphological Restructuring of Myocardium During the Early Phase of Experimental Diabetes Mellitus". Anat. Rec. 298 (2): 396–407. doi:10.1002/ar.23052. hdl:10995/73117. PMID25251897. S2CID205412167.
Tyrberg, B.; Andersson, A.; Borg, L. A. (2001). "Species Differences in Susceptibility of Transplanted and Cultured Pancreatic Islets to the β-Cell Toxin Alloxan". General and Comparative Endocrinology. 122 (3): 238–251. doi:10.1006/gcen.2001.7638. PMID11356036.
F. Wöhler und J. Liebig (1838) "Untersuchungen über die Natur der Harnsäure" (Investigations into the nature of uric acid), Annalen der Chemie und Pharmacie, 26 : 241-340. Alloxan is named on p. 252 and its preparation and properties appear on pp. 256 ff.
Mrozikiewicz, A.; Kielstrokczewska-Mrozikiewicz, D.; Lstrokowicki, Z.; Chmara, E.; Korzeniowska, K.; Mrozikiewicz, P. M. (1994). "Blood Levels of Alloxan in Children with Insulin-dependent Diabetes Mellitus". Acta Diabetologica. 31 (4): 236–237. doi:10.1007/bf00571958. PMID7888696. S2CID12726659.
Danilova I.G.; Sarapultsev P.A.; Medvedeva S.U.; Gette I.F.; Bulavintceva T.S.; Sarapultsev A.P. (2014). "Morphological Restructuring of Myocardium During the Early Phase of Experimental Diabetes Mellitus". Anat. Rec. 298 (2): 396–407. doi:10.1002/ar.23052. hdl:10995/73117. PMID25251897. S2CID205412167.
Szkudelski T (2001). "The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas". Physiol Res. 50 (6): 536–546. PMID11829314.
Tyrberg, B.; Andersson, A.; Borg, L. A. (2001). "Species Differences in Susceptibility of Transplanted and Cultured Pancreatic Islets to the β-Cell Toxin Alloxan". General and Comparative Endocrinology. 122 (3): 238–251. doi:10.1006/gcen.2001.7638. PMID11356036.
Lenzen, Sigurd[in German]; Munday, Rex (September 1991). "Thiol-group reactivity, hydrophilicity and stability of alloxan, its reduction products and its N-methyl derivatives and a comparison with ninhydrin". Biochemical Pharmacology. 42 (7): 1385–1391. doi:10.1016/0006-2952(91)90449-F.